Development of novel inhibitors targeting ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Development of novel inhibitors targeting the d-box of the dna binding domain of androgen receptor
Auteur(s) :
Radaeva, Mariia [Auteur]
Ban, Fuqiang [Auteur]
Zhang, Fan [Auteur]
Leblanc, Eric [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Lallous, Nada [Auteur]
Rennie, Paul S. [Auteur]
Gleave, Martin E. [Auteur]
Cherkasov, Artem [Auteur]
Ban, Fuqiang [Auteur]
Zhang, Fan [Auteur]
Leblanc, Eric [Auteur]

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Lallous, Nada [Auteur]
Rennie, Paul S. [Auteur]
Gleave, Martin E. [Auteur]
Cherkasov, Artem [Auteur]
Titre de la revue :
International Journal of Molecular Sciences
Nom court de la revue :
Int. J. Mol. Sci.
Numéro :
22
Pagination :
2493
Date de publication :
2021-03-02
ISSN :
1422-0067
Mot(s)-clé(s) :
androgen receptor
prostate cancer
small-molecule inhibitors
computer-aided drug discovery
dimerization
prostate cancer
small-molecule inhibitors
computer-aided drug discovery
dimerization
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The inhibition of the androgen receptor (AR) is an established strategy in prostate cancer (PCa) treatment until drug resistance develops either through mutations in the ligand-binding domain (LBD) portion of the receptor ...
Lire la suite >The inhibition of the androgen receptor (AR) is an established strategy in prostate cancer (PCa) treatment until drug resistance develops either through mutations in the ligand-binding domain (LBD) portion of the receptor or its deletion. We previously identified a druggable pocket on the DNA binding domain (DBD) dimerization surface of the AR and reported several potent inhibitors that effectively disrupted DBD-DBD interactions and consequently demonstrated certain antineoplastic activity. Here we describe further development of small molecule inhibitors of AR DBD dimerization and provide their broad biological characterization. The developed compounds demonstrate improved activity in the mammalian two-hybrid assay, enhanced inhibition of AR-V7 transcriptional activity, and improved microsomal stability. These findings position us for the development of AR inhibitors with entirely novel mechanisms of action that would bypass most forms of PCa treatment resistance, including the truncation of the LBD of the AR.Lire moins >
Lire la suite >The inhibition of the androgen receptor (AR) is an established strategy in prostate cancer (PCa) treatment until drug resistance develops either through mutations in the ligand-binding domain (LBD) portion of the receptor or its deletion. We previously identified a druggable pocket on the DNA binding domain (DBD) dimerization surface of the AR and reported several potent inhibitors that effectively disrupted DBD-DBD interactions and consequently demonstrated certain antineoplastic activity. Here we describe further development of small molecule inhibitors of AR DBD dimerization and provide their broad biological characterization. The developed compounds demonstrate improved activity in the mammalian two-hybrid assay, enhanced inhibition of AR-V7 transcriptional activity, and improved microsomal stability. These findings position us for the development of AR inhibitors with entirely novel mechanisms of action that would bypass most forms of PCa treatment resistance, including the truncation of the LBD of the AR.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Date de dépôt :
2022-06-15T14:00:05Z
2023-03-08T10:02:32Z
2023-03-08T10:02:32Z
Fichiers
- 2021-03-01-ijms-22-02493.pdf
- Version éditeur
- Accès libre
- Accéder au document